Telemetry Investments’s Travere Therapeutics TVTX Stock Holding History

Telemetry Investments’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-21,695	Closed	-$491K	–	110
2019 Q1	$491K	Buy	+21,695	New	+$479K	0.25%	53
2018 Q3	–	Sell	-42,000	Closed	-$1.15M	–	153
2018 Q2	$1.15M	Sell	42,000 -20,960	-33%	-$558K	0.44%	35
2018 Q1	$1.41M	Buy	62,960 +2,624	+4%	+$62.5K	0.53%	37
2017 Q4	$1.27M	Buy	60,336 +19,336	+47%	+$442K	0.48%	39
2017 Q3	$1.02M	Sell	41,000 -19,000	-32%	-$418K	0.36%	44
2017 Q2	$1.16M	Buy	60,000 +16,000	+36%	+$290K	0.55%	38
2017 Q1	$812K	Buy	44,000 +6,000	+16%	+$117K	0.36%	41
2016 Q4	$719K	Buy	38,000 +3,734	+11%	+$76.4K	0.41%	43
2016 Q3	$767K	Sell	34,266 -35,734	-51%	-$680K	0.48%	37
2016 Q2	$1.25M	Sell	70,000 -94,153	-57%	-$1.52M	0.67%	30
2016 Q1	$2.24M	Sell	164,153 -15,847	-9%	-$240K	0.65%	26
2015 Q4	$3.47M	Buy	180,000 +32,000	+22%	+$639K	1.18%	21
2015 Q3	$3M	Sell	148,000 -2,500	-2%	-$74.1K	1.28%	23
2015 Q2	$4.99M	Buy	150,500 +70,900	+89%	+$1.94M	2.25%	12
2015 Q1	$1.91M	Buy	79,600 +61,100	+330%	+$932K	1.05%	26
2014 Q4	$226K	Buy	+18,500	New	+$191K	0.14%	144

Other funds holding TVTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Telemetry Investments's TVTX Position: Q2 2019 in Review

Telemetry Investments sold out of Travere Therapeutics (TVTX) in Q2 2019, closing a stake of 21,695 shares — an estimated $491K sold.

Telemetry Investments first reported a position in TVTX in Q4 2014 and held it in 16 quarters. The position peaked at $4.99M in Q2 2015. 122 funds tracked by Wall St. Rank hold TVTX as of Q2 2019.

Telemetry Investments reported no remaining Travere Therapeutics position as of Q2 2019 after selling out during the quarter.
Telemetry Investments sold 21,695 Travere Therapeutics shares in Q2 2019, an estimated $491K.
Telemetry Investments first reported a position in Travere Therapeutics in Q4 2014 and held it in 16 quarters.
Telemetry Investments's Travere Therapeutics position peaked at $4.99M in Q2 2015.
122 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2019.

Based on Telemetry Investments's 13F filing for Q2 2019, filed 14 Aug 2019.